August 5, 2013 6:04 PM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Quidel Corporation(NASDAQ: QDEL), a provider of rapid diagnostic testing solutions,cell-based virology assays and molecular diagnostic systems,announced today that it has received 510(k) clearance from the UnitedStates Food and Drug Administration (FDA) for its Sofia(R) hCGfluorescent immunoassay for use on the Sofia Analyzer for the rapid,objective detection of elevated levels of human chorionicgonadotropin (hCG), an early indicator of pregnancy. Sofia is the brand name for Quidel's next-generation, immunoassaysystem. The Sofia Analyzer and Sofia hCG FIA with proprietary KineticCheck(TM) Technology combine unique immunofluorescence chemistry,advanced lateral flow technology, and failure alert and fail-safesystems designed to ensure a reliable, objective, highly accurate,diagnostic result within three (3) minutes of application of thepatient's specimen.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.